Celiac disease in pregnant women has been associated with poor growth of the fetus, but little is known about how the level of celiac disease affects fetal growth or birth outcomes.
We assessed the associations between levels of antibodies against tissue transglutaminase and fetal growth and birth outcomes for pregnant women.
Dr Jessica C. Kiefte–de Jong reported that they performed a population-based prospective birth cohort study of 7046 pregnant women.
Serum samples were collected during the second trimester of pregnancy and analyzed for levels of anti-tTG.
The researchers examined that based on these levels, the women were categorized into 3 groups: negative anti-tTG, intermediate anti-tTG, or positive anti-tTG.
Data on fetal growth and birth outcomes were collected from ultrasound measurements and medical records.
|The calculated pooled gastric cancer incidence-rate was about 0.3% per person-years|
The researchers reported that fetuses of women in the positive anti-tTG group weighed 16 g less than those of women in the negative anti-tTG group during the third trimester.
Newborns of women in the intermediate and positive anti-tTG groups weighed 53 g and 159 g less at birth, respectively, than those of women in the negative anti-tTG group.
The team of doctors noted that the reduction in birth weight in offspring of mothers in the intermediate anti-tTG group was 2-fold greater among mothers who carried HLA-DQ2 or -DQ8 than among those without HLA-DQ2 or -DQ8.
Dr Jessica's team commented "Levels of anti-tTG in pregnant women are inversely associated with fetal growth."
"Growth was reduced to the greatest extent in fetuses of women with the highest levels of anti-tTG."
"Birth weight was also reduced in women with intermediate levels of anti-tTG and further reduced in those carrying HLA-DQ2 and -DQ8."